Renee P. Tannenbaum, Pharm.D., 74, has served as a director since March 2022. Since March 2025, Dr. Tannenbaum has served as Corporate Development Advisor for Bench International, an executive search firm focused on biotech and life sciences. Previously, she served as Vice President of Global Partnering at Halozyme, Inc. from August 2016 to July 2021, where she was responsible for leading the team that executed business development activities and the company's alliances through partnerships and collaborations. Prior to that, Dr. Tannenbaum was Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization. Dr. Tannenbaum has extensive experience as a Board member and a strategic advisor. She has served since June 2021 as a director at Cardiff Oncology, Inc., and previously served as a director of Zogenix, Inc. from 2015 until 2022, both U.S. publicly traded companies. She has also served as a director for foreign publicly traded companies Nordic Nanovector ASA and Cipher Pharmaceuticals, Inc., and Sharps Compliance, Inc., and the privately held company Immune Pharmaceuticals, Inc. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her M.B.A. from Temple University, and her B.S. in Pharmacy from the University of Connecticut. Dr. Tannenbaum is qualified to serve on our Board based on her extensive executive leadership experience in the pharmaceutical and biopharmaceutical industries and her current and past experience as a director of several U.S. and foreign publicly traded companies. Dr. Tannenbaum is currently a member of the Board's Compensation Committee and Chair of the Board's Nominating and Corporate Governance Committee.